Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Gains from Investment Securities (2020 - 2023)

Historic Gains from Investment Securities for Candel Therapeutics (CADL) over the last 4 years, with Q4 2023 value amounting to $483000.0.

  • Candel Therapeutics' Gains from Investment Securities rose 11760.2% to $483000.0 in Q4 2023 from the same period last year, while for Dec 2023 it was -$3.2 million, marking a year-over-year increase of 8141.78%. This contributed to the annual value of $20.8 million for FY2024, which is 225341.61% up from last year.
  • According to the latest figures from Q4 2023, Candel Therapeutics' Gains from Investment Securities is $483000.0, which was up 11760.2% from -$581000.0 recorded in Q3 2023.
  • Candel Therapeutics' Gains from Investment Securities' 5-year high stood at $8.2 million during Q3 2021, with a 5-year trough of -$9.2 million in Q4 2021.
  • For the 4-year period, Candel Therapeutics' Gains from Investment Securities averaged around $1.2 million, with its median value being $483000.0 (2023).
  • Over the last 5 years, Candel Therapeutics' Gains from Investment Securities had its largest YoY gain of 2834827.59% in 2021, and its largest YoY loss of 30331.56% in 2021.
  • Candel Therapeutics' Gains from Investment Securities (Quarter) stood at $4.5 million in 2020, then tumbled by 303.32% to -$9.2 million in 2021, then soared by 70.17% to -$2.7 million in 2022, then skyrocketed by 117.6% to $483000.0 in 2023.
  • Its last three reported values are $483000.0 in Q4 2023, -$581000.0 for Q3 2023, and $6.4 million during Q2 2023.